中国医学前沿杂志（电子版）2023，Vol.15Issue(11)：65-70,6.DOI:10.12037/YXQY.2023.11-10
贝利尤单抗治疗活动性狼疮性肾炎的临床疗效及不良反应
Clinical efficacy and adverse reactions of belimumab in the treatment of active lupus nephritis
王敏 1王明霞 1邹婵娟 1颜丝语 1何善智 1丁菱1
作者信息
- 1. 中山市人民医院 风湿免疫科,广东 中山 528400
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy and adverse reactions of belimumab in the treatment of active lupus nephritis(LN).Methods A retrospective analysis was performed on 46 patients with active LN admitted to the Rheumatology Department of Zhongshan People's Hospital from August 2020 to August 2023.All patients were treated with beliuzumab combined with standard of care(SoC)for more than 6 months.The clinical efficacy,glucocorticoid dosage and incidence of adverse reactions were evaluated.SoC refers to glucocorticoid,antimalarial,and immunosuppressive therapy.Results After 24 weeks of beliuzumab treatment,SLE disease activity index(SLEDAI),24-hour urinary protein quantification,glucocorticoid dosage,interleukin(IL)-10 and B lymphocytes ratio decreased compared with those before treatment(P<0.05),while the levels of albumin,complement 3(C3)significantly increased(P<0.05).The 24-hour urinary protein response rate of LN patients was 78.3%(36/46),and the partial response rate was 17.4%(8/46).Two patients had recurrence,and the total response rate was 95.7%.Complete remission rate and low disease activity status of lupus were 17.4%and 26.1%respectively.There were 5 adverse events(10.9%),including 1 case of upper respiratory tract infection,2 cases of herpes zoster,1 case of salmonella infection,and 1 case of dizziness and discomfort.Conclusions Beliuzumab combined with standard of care in the treatment of adult active LN show the overall efficacy,improvement of disease activity,reduction of urinary protein and the decrease of glucocorticoid dosage.It can improve the serological indicators and the kidney damage indicators with a very low incidence of adverse reactions.关键词
狼疮性肾炎/贝利尤单抗/疗效/不良反应Key words
Lupus nephritis/Belimumab/Curative effect/Adverse reaction引用本文复制引用
王敏,王明霞,邹婵娟,颜丝语,何善智,丁菱..贝利尤单抗治疗活动性狼疮性肾炎的临床疗效及不良反应[J].中国医学前沿杂志（电子版）,2023,15(11):65-70,6.
